00:15:05 EDT Sat 24 Aug 2019
Enter Symbol
or Name

Login ID:
Clovis Oncology, Inc.
Symbol U : CLVS
Recent Sedar Documents

Clovis Oncology to Announce Third Quarter 2018 Financial Results and Host Webcast Conference Call on October 30

2018-10-16 08:00 ET - News Release

BOULDER, Colo. -- (Business Wire)

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2018 financial results on Tuesday, October 30, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail.

The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.

Conference Call Details

Clovis will hold a conference call to discuss third quarter 2018 results on October 30 at 4:30 p.m. ET. The conference call will be simultaneously webcast on the Company’s web site at www.clovisoncology.com, and archived for future review. Dial-in numbers for the conference call are as follows: US participants 866.393.4306, International participants 734.385.2616; conference ID: 5885294.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco and Oakland, California and Cambridge, UK. Please visit clovisoncology.com for more information.


Clovis Investor Contacts:
Anna Sussman, 303-625-5022
Breanna Burkart, 303-625-5023

Source: Clovis Oncology, Inc.

© 2019 Canjex Publishing Ltd. All rights reserved.